Coagulation Studies Mastery

🩸

Understanding Coagulation

Hemostasis is the physiological process that stops bleeding through a coordinated sequence involving primary hemostasis (platelet plug formation) and secondary hemostasis (coagulation cascade). Understanding the cascade is essential for interpreting coagulation studies and diagnosing bleeding disorders.

📚 Evidence: Current model based on cell-based coagulation theory (Hoffman & Monroe, 2001)

🔴 Primary Hemostasis

Players: Platelets, von Willebrand factor (vWF), endothelium
Process: Vascular injury → platelet adhesion → activation → aggregation
Result: Platelet plug (temporary seal)
Timing: Seconds to minutes
Assessed by: Platelet count, bleeding time (obsolete), PFA-100

🧬 Secondary Hemostasis

Players: Coagulation factors (I-XIII), calcium
Process: Coagulation cascade activation → thrombin generation
Result: Fibrin clot (permanent seal)
Timing: Minutes
Assessed by: PT/INR, aPTT, thrombin time, factor assays

⚡

The Coagulation Cascade

The traditional model divides coagulation into three pathways: Intrinsic, Extrinsic, and Common. While the cell-based model is more physiologically accurate, the cascade model remains useful for understanding laboratory testing.

Coagulation Cascade - Traditional Model

Intrinsic Pathway
(Measured by aPTT)

Contact Activation

↓

XII → XIIa

↓

XI → XIa

↓

IX → IXa

↓

VIII + IXa + PL + Ca²⁺
(Tenase Complex)

↓

Extrinsic Pathway
(Measured by PT/INR)

Tissue Factor (TF)

↓

VII + TF

↓

VIIa-TF Complex

↓

→

Common Pathway
(Measured by Both PT & aPTT)

X → Xa

↓

V + Xa + PL + Ca²⁺
(Prothrombinase Complex)

↓

Prothrombin (II) → Thrombin (IIa)

↓

Fibrinogen (I) → Fibrin (Ia)

↓

XIII + Fibrin → Cross-linked Fibrin

↓

✓ STABLE CLOT

Clinical Pearl: Memory Aid

Intrinsic pathway factors: "12, 11, 9, 8" - Contact factors going down
Extrinsic pathway: Just Factor VII (lucky 7 is quick!)
Common pathway: "10, 5, 2, 1, 13" - Final common path to clot
Vitamin K-dependent factors: "2, 7, 9, 10" + Protein C & S (remember: 1972!)

📋

Key Coagulation Factors

Factor	Name	Pathway	Half-Life	Vitamin K-Dependent?
I	Fibrinogen	Common	3-5 days	No
II	Prothrombin	Common	2-3 days	Yes
V	Labile factor	Common	12-36 hours	No
VII	Stable factor	Extrinsic	4-6 hours (shortest!)	Yes
VIII	Antihemophilic factor	Intrinsic	8-12 hours	No
IX	Christmas factor	Intrinsic	24 hours	Yes
X	Stuart-Prower factor	Common	24-48 hours	Yes
XI	Plasma thromboplastin antecedent	Intrinsic	40-80 hours	No
XII	Hageman factor	Intrinsic	48-52 hours	No
XIII	Fibrin-stabilizing factor	Common (final)	9-12 days	No

🔑 Vitamin K-Dependent Factors

Factors II, VII, IX, X + Protein C & Protein S (natural anticoagulants)

Clinical significance:

Require vitamin K for gamma-carboxylation (activation)
Inhibited by warfarin (blocks vitamin K epoxide reductase)
Factor VII has shortest half-life → PT rises first with warfarin
Deficiency in liver disease (decreased synthesis) or malabsorption

🛡️

Natural Anticoagulants

Protein C

Function: Inactivates factors Va and VIIIa

Cofactor: Protein S (vitamin K-dependent)

Activation: By thrombin-thrombomodulin complex

Deficiency: Thrombophilia, warfarin necrosis risk

Protein S

Function: Cofactor for Protein C

Forms: Free (active) and bound to C4b-binding protein

Vitamin K-dependent: Yes

Deficiency: Thrombophilia, pregnancy-related thrombosis

Antithrombin (AT)

Function: Inhibits thrombin (IIa), Xa, IXa, XIa

Enhanced by: Heparin (1000x increase in activity)

NOT vitamin K-dependent

Deficiency: Severe thrombophilia, heparin resistance

📊

Prothrombin Time (PT) & INR

What PT Measures

Principle: Time for plasma to clot after addition of tissue factor (thromboplastin) and calcium

Evaluates:

Extrinsic pathway: Factor VII
Common pathway: Factors X, V, II, I
Overall: Vitamin K-dependent factors (II, VII, X)

Normal range: 11-13.5 seconds (varies by lab)

International Normalized Ratio (INR)

Purpose: Standardize PT results across different labs/reagents

Calculation:

INR = (PT patient / PT normal)^ISI

ISI = International Sensitivity Index (reagent-specific)

Normal INR: 0.8-1.2

Therapeutic INR: 2.0-3.0 (most indications)

Why INR Matters

PT values vary significantly between laboratories due to different thromboplastin reagents. A PT of 15 seconds might be normal in one lab but abnormal in another. INR standardizes results, making warfarin monitoring consistent worldwide. Always use INR for warfarin monitoring, not raw PT values!

💊

Warfarin Monitoring & Management

Warfarin Mechanism of Action

Target: Vitamin K epoxide reductase (VKORC1)

Effect: Prevents recycling of vitamin K → decreased synthesis of factors II, VII, IX, X + Protein C & S

Onset: 36-72 hours (reflects Factor VII depletion - shortest half-life at 4-6 hours)

Peak effect: 5-7 days (when Factor II depleted - longest half-life)

Duration: 2-5 days after stopping

Indication	Target INR	Duration
DVT/PE Treatment	2.0-3.0	3 months (provoked) to lifelong (unprovoked, recurrent)
Atrial Fibrillation	2.0-3.0	Lifelong (if CHA₂DS₂-VASc ≥2)
Mechanical Heart Valve (Aortic)	2.0-3.0	Lifelong
Mechanical Heart Valve (Mitral)	2.5-3.5	Lifelong
Antiphospholipid Syndrome (APS)	2.0-3.0	Lifelong (after thrombosis)
Recurrent VTE on standard therapy	2.5-3.5	Lifelong

Warfarin Dosing Algorithm

Initial Dosing

Start: 5 mg daily (consider 2.5-3 mg in elderly, Asian patients, or low body weight)

Check INR: In 2-3 days, then 1-2 times per week until stable

Dose Adjustment

If INR < 2.0: Increase weekly dose by 5-20%

If INR 2.0-3.0: Continue current dose (goal achieved!)

If INR 3.1-4.0: Decrease weekly dose by 5-15%

If INR > 4.0: Hold dose, check for bleeding, restart at lower dose when INR therapeutic

Stable Monitoring

Once stable (3 consecutive INRs in range): Check INR every 4 weeks

After dose change: Check INR in 1-2 weeks

After medication change: Check INR in 3-7 days

Warfarin Drug Interactions (Critical!)

↑ INR (bleeding risk): Antibiotics (especially metronidazole, TMP-SMX, macrolides), amiodarone, acetaminophen (high dose), NSAIDs, SSRIs

↓ INR (clot risk): Rifampin, carbamazepine, phenytoin, St. John's Wort, vitamin K-rich foods

⚠️ Always check INR 3-7 days after starting/stopping any medication in patients on warfarin!

🚨

Managing Elevated INR

INR	Bleeding?	Management
3.1-4.5	No	• Omit next 1-2 doses • Resume at lower dose when INR therapeutic • Monitor closely
4.6-10	No	• Hold warfarin • Consider Vitamin K 1-2.5 mg PO if high bleeding risk • Resume at lower dose when INR < 3
> 10	No	• Hold warfarin • Vitamin K 2.5-5 mg PO • Check INR daily • Resume at lower dose when INR therapeutic
Any	Serious bleeding	• Hold warfarin • 4-Factor PCC 25-50 units/kg IV (preferred) OR FFP 10-15 mL/kg • Vitamin K 10 mg IV slow infusion • Supportive care, transfusions as needed
Any	Life-threatening bleeding	• 4-Factor PCC 50 units/kg IV STAT • Vitamin K 10 mg IV • ICU admission • Surgery/IR consult as appropriate

Reversal Agent Pearls

Vitamin K (Phytonadione): Takes 12-24 hours for full effect; may cause warfarin resistance for several days
4-Factor PCC (Prothrombin Complex Concentrate): Immediate reversal; preferred over FFP (faster, no volume overload, no blood type matching needed)
FFP (Fresh Frozen Plasma): Alternative if PCC unavailable; requires large volumes (10-15 mL/kg), risk of TACO
⚠️ Anaphylaxis risk with IV vitamin K - give slow infusion over 20-30 minutes!

🔄

Bridging Anticoagulation

When to Bridge?

Concept: Use short-acting anticoagulant (LMWH or heparin) when warfarin is held for procedures

HIGH-RISK (usually bridge):

Mechanical mitral valve
Mechanical aortic valve + additional risk factors
VTE within 3 months
Severe thrombophilia (e.g., antiphospholipid syndrome)

LOW-RISK (usually NO bridge):

Atrial fibrillation (even with prior stroke if > 3 months ago)
VTE > 12 months ago
Bioprosthetic valve

📚 BRIDGE Trial (2015): Bridging increased bleeding without reducing thrombosis in AF patients

Bridging Protocol (if indicated)

Pre-procedure:
• Stop warfarin 5 days before procedure
• Start LMWH (enoxaparin 1 mg/kg SC BID) when INR < 2.0
• Last dose of LMWH 24 hours before procedure

Post-procedure:
• Resume warfarin on evening of procedure (if hemostasis adequate)
• Resume LMWH 24 hours post-procedure (minor) or 48-72 hours (major)
• Stop LMWH when INR ≥ 2.0 for 24 hours

⏱️

Activated Partial Thromboplastin Time (aPTT)

What aPTT Measures

Principle: Time for plasma to clot after adding activator, phospholipid, and calcium

Evaluates:

Intrinsic pathway: XII, XI, IX, VIII
Common pathway: X, V, II, I

Normal range: 25-35 seconds (lab-specific)

Therapeutic range (heparin): 1.5-2.5 × control (typically 60-80 seconds)

Clinical Uses

Monitor unfractionated heparin (UFH) therapy
Screen for intrinsic pathway deficiencies (hemophilia A & B)
Detect lupus anticoagulant (paradoxically prolonged)
Evaluate unexplained bleeding
Pre-operative screening (controversial utility)

⚠️ NOT used for: LMWH, fondaparinux, DOACs (use anti-Xa for LMWH)

💉

Heparin Monitoring with aPTT

Unfractionated Heparin (UFH) Basics

Mechanism: Binds antithrombin → 1000x increased inhibition of thrombin (IIa) and factor Xa

Route: IV (for acute anticoagulation) or SC (prophylaxis)

Onset: Immediate

Half-life: 60-90 minutes

Monitoring: aPTT (goal: 1.5-2.5 × control or 60-80 seconds)

Reversal: Protamine sulfate (1 mg neutralizes ~100 units heparin)

Weight-Based Heparin Protocol

Initial Dosing

Bolus: 80 units/kg IV (max 10,000 units)

Infusion: 18 units/kg/hour

Check aPTT: 6 hours after initiation, then 6 hours after each dose change

Dose Adjustment Based on aPTT

aPTT < 35 sec (< 1.2 × control):
• Bolus 80 units/kg
• Increase infusion by 4 units/kg/hr

aPTT 35-45 sec (1.2-1.5 × control):
• Bolus 40 units/kg
• Increase infusion by 2 units/kg/hr

aPTT 46-70 sec (1.5-2.3 × control):
• THERAPEUTIC - No change

aPTT 71-90 sec (2.3-3.0 × control):
• Decrease infusion by 2 units/kg/hr

aPTT > 90 sec (> 3.0 × control):
• Hold infusion for 1 hour
• Decrease infusion by 3 units/kg/hr
• Recheck aPTT in 6 hours

Maintenance Monitoring

Once therapeutic: Check aPTT daily (or every 12 hours initially)

Duration: Continue until transition to oral anticoagulation (overlap for 48 hours with INR ≥ 2.0)

Heparin-Induced Thrombocytopenia (HIT)

Incidence: 1-5% with UFH (lower with LMWH)

Timing: Typically days 5-10 of therapy (can be earlier if prior exposure)

Diagnosis: Platelet count drop > 50% + positive HIT antibody (PF4-heparin complex)

Consequence: PARADOXICAL THROMBOSIS (venous > arterial)

Management:
• STOP all heparin immediately (including flushes, LMWH, lines)
• Start alternative anticoagulant (argatroban, bivalirudin, fondaparinux)
• DO NOT give warfarin until platelets recover (risk of limb gangrene)
• Check for thrombosis (Doppler US)

⚠️ Monitor platelets every 2-3 days while on heparin!

🔍

Differential Diagnosis of Prolonged aPTT

Category	Causes	PT Status	Key Features
Factor Deficiencies	• Hemophilia A (Factor VIII) • Hemophilia B (Factor IX) • Factor XI deficiency • Factor XII deficiency	Normal	Bleeding (except XII - NO bleeding!)
Anticoagulants	• Unfractionated heparin • Direct thrombin inhibitors • Some DOACs (dabigatran)	May be ↑	Medication history
Lupus Anticoagulant	• Antiphospholipid syndrome • SLE • Infections (transient)	May be ↑	THROMBOSIS, not bleeding! Does NOT correct with mixing
Von Willebrand Disease	• vWF deficiency/dysfunction	Normal	↓ Factor VIII (vWF stabilizes VIII) Mucocutaneous bleeding ↑ bleeding time
Liver Disease	• Decreased factor synthesis	Also ↑	Multiple factors affected ↓ Platelets often present
DIC	• Consumption of factors	Also ↑	↓ Fibrinogen, ↑ D-dimer ↓ Platelets, ↑ PT

Factor XII Deficiency - The Exception!

Paradox: Prolonged aPTT but NO clinical bleeding

Why? Factor XII is important for in vitro clotting but not essential for in vivo hemostasis

Clinical significance: No treatment needed; may be incidental finding; important to recognize to avoid unnecessary workup/treatment

Remember: Contact factors (XII, XI, prekallikrein, HMWK) deficiency → prolonged aPTT but variable bleeding

🧪

Mixing Studies: The Key to Diagnosis

Mixing studies distinguish between factor deficiency (bleeding disorder) and inhibitor presence (lupus anticoagulant or acquired inhibitor). This is THE critical test when PT or aPTT is prolonged.

The Concept

Principle: Mix patient's plasma 1:1 with normal pooled plasma (NPP)

Rationale: NPP contains 100% of all coagulation factors

Result interpretation:

Corrects (normalizes): Factor deficiency (NPP provides missing factors)
Does NOT correct: Inhibitor present (inhibitor blocks added factors too)

Timing: Test immediately (0 min) and after incubation (1-2 hours at 37°C)

📚 Evidence: CLSI H47-A2 Guidelines for Lupus Anticoagulant Testing

📊

Interpreting Mixing Study Results

Result	Immediate Mix	After Incubation	Interpretation	Next Steps
Complete Correction	Corrects	Stays corrected	Factor deficiency	• Perform factor assays • Check specific factor levels • Clinical correlation
No Correction	No correction	No correction	Immediate inhibitor (e.g., Lupus anticoagulant, heparin)	• Lupus anticoagulant panel • Check for heparin contamination • Specific inhibitor assays
Delayed Inhibitor	Corrects	Loses correction	Time-dependent inhibitor (e.g., Factor VIII inhibitor)	• Factor VIII inhibitor assay (Bethesda) • Check for acquired hemophilia • Consider autoimmune workup

Correction Criteria

"Correction" means: Mixed PT or aPTT is within 10-15% of normal control (lab-specific cutoff)

Example:
• Normal aPTT control: 30 seconds
• Patient aPTT: 60 seconds (prolonged)
• 1:1 Mix aPTT: 34 seconds → CORRECTED (within 15% of 30)
• 1:1 Mix aPTT: 52 seconds → NOT CORRECTED (still > 15% above normal)

🎯

Clinical Scenarios & Patterns

Scenario 1: Hemophilia A

Clinical: Male with lifelong bleeding, hemarthrosis

Labs:
• aPTT: Prolonged
• PT: Normal
• Mixing: Corrects

Diagnosis: Factor VIII deficiency

Confirm: Factor VIII assay (< 1% = severe)

Treatment: Factor VIII concentrate

Scenario 2: Lupus Anticoagulant

Clinical: Woman with recurrent DVT, miscarriages

Labs:
• aPTT: Prolonged
• PT: May be prolonged
• Mixing: Does NOT correct

Diagnosis: Antiphospholipid antibody

Confirm: Lupus anticoagulant panel, anti-cardiolipin, anti-β2GP1

Paradox: THROMBOSIS, not bleeding!

Scenario 3: Acquired Hemophilia

Clinical: Elderly patient, no prior bleeding, now with spontaneous bruising

Labs:
• aPTT: Markedly prolonged
• PT: Normal
• Mixing: Corrects initially → Loses correction after incubation

Diagnosis: Acquired Factor VIII inhibitor (autoantibody)

Confirm: Bethesda assay (measures inhibitor titer)

Treatment: Bypass agents (FEIBA, rVIIa), immunosuppression

Scenario 4: Heparin Contamination

Clinical: Patient on heparin drip, routine labs

Labs:
• aPTT: Prolonged
• PT: May be prolonged
• Mixing: Does NOT correct

Diagnosis: Heparin effect (iatrogenic)

Confirm: Thrombin time (very prolonged), clinical context

Solution: Draw from peripheral site (not from line), repeat sample

🧮

Interactive Mixing Study Calculator

Calculate % Correction

Use this calculator to determine if a mixing study shows correction

Normal Control (seconds):

Patient Value (seconds):

1:1 Mix Value (seconds):

Results:

⚠️

Pitfalls & Troubleshooting

Common Mixing Study Pitfalls

Heparin contamination: Most common cause of falsely prolonged aPTT with non-correction. Draw from peripheral vein, not from line!
Weak factor VIII inhibitors: May only show delayed non-correction (after incubation). Always incubate samples!
Multiple abnormalities: Patient may have both deficiency AND inhibitor (e.g., hemophiliac who developed inhibitor). Partial correction may occur.
Lupus anticoagulant in hemophiliac: Rare but possible. Both prolonged aPTT and thrombotic risk!
Very low factor levels: 50% from NPP may not be enough. May need to repeat with higher NPP ratio or check factor levels directly.

When Mixing Study is Equivocal

If results are borderline or confusing:

Repeat with fresh samples (factors degrade over time)
Perform specific factor assays (VIII, IX, XI, XII)
Check thrombin time (detects heparin, fibrinogen issues)
Consider lupus anticoagulant panel regardless (dRVVT, dilute PT)
Review clinical history - does patient have bleeding or clotting?

Remember: Clinical context is key! Lab results must make sense with patient's presentation.

🔍

Approach to Bleeding Disorders

Systematic Bleeding Disorder Workup

History & Physical

Key questions:

Age of onset (congenital vs. acquired)
Bleeding pattern (mucocutaneous vs. deep tissue/joints)
Family history (inheritance pattern)
Medications (anticoagulants, antiplatelets, SSRIs)
Associated conditions (liver disease, renal failure, malignancy)

Initial Laboratory Testing

First-line tests:

CBC with differential: Platelet count, RBC parameters
PT/INR: Extrinsic + common pathway
aPTT: Intrinsic + common pathway
Fibrinogen: Common pathway, DIC screening

Mixing Studies (if PT or aPTT prolonged)

Determines: Factor deficiency vs. inhibitor

Guide further testing: Factor assays vs. inhibitor workup

Specialized Testing (based on pattern)

If mucocutaneous bleeding: vWF testing, platelet function

If joint/muscle bleeding: Factor VIII, IX assays

If surgery-related: Factor XIII, plasminogen, α2-antiplasmin

📊

Interpretation Algorithm

PT	aPTT	Platelets	Most Likely Diagnosis
Normal	Normal	Low	• Thrombocytopenia (ITP, drug-induced, marrow failure) • Platelet dysfunction • von Willebrand disease (mild)
Normal	↑	Normal	• Hemophilia A or B (VIII, IX deficiency) • Factor XI deficiency • von Willebrand disease • Heparin effect • Lupus anticoagulant
↑	Normal	Normal	• Factor VII deficiency (rare) • Early warfarin effect • Vitamin K deficiency (early) • Mild liver disease
↑	↑	Normal	• Common pathway deficiency (II, V, X, fibrinogen) • Warfarin (therapeutic or supratherapeutic) • Liver disease • Vitamin K deficiency • DIC (early)
↑	↑	Low	• DIC (most common!) • Severe liver disease • Massive transfusion • Combined defects

Pattern Recognition Pearls

Isolated aPTT prolongation + correction with mixing: Think hemophilia A/B (most common congenital bleeding disorder in males)
Isolated aPTT prolongation + NO correction with mixing: Lupus anticoagulant (thrombosis risk, NOT bleeding!)
Both PT & aPTT elevated + low platelets + low fibrinogen: DIC until proven otherwise
Normal PT/aPTT but significant bleeding: Consider platelet dysfunction, vWD, Factor XIII deficiency, or vascular disorder

🩸

Common Bleeding Disorders

Hemophilia A (Factor VIII Deficiency)

Genetics: X-linked recessive (affects males)

Incidence: 1 in 5,000 male births

Clinical: Hemarthrosis, deep muscle hematomas, CNS bleeding

Labs:
• aPTT: Prolonged
• PT: Normal
• Factor VIII: < 1% (severe), 1-5% (moderate), 5-40% (mild)
• Mixing: Corrects (unless inhibitor developed)

Treatment: Factor VIII concentrate, desmopressin (mild cases)

Hemophilia B (Factor IX Deficiency)

Genetics: X-linked recessive

Incidence: 1 in 25,000 male births (5× less common than A)

Clinical: Identical to Hemophilia A

Labs:
• aPTT: Prolonged
• PT: Normal
• Factor IX: Low
• Cannot distinguish from A without factor assays!

Treatment: Factor IX concentrate (different from VIII!)

Von Willebrand Disease (vWD)

Genetics: Autosomal dominant (most common)

Incidence: 1% of population (most common inherited bleeding disorder!)

Clinical: Mucocutaneous bleeding (epistaxis, menorrhagia, easy bruising)

Labs:
• aPTT: Often prolonged (↓ vWF → ↓ Factor VIII)
• PT: Normal
• vWF antigen: Low
• Ristocetin cofactor activity: Low

Treatment: Desmopressin (Type 1), vWF/VIII concentrate

Vitamin K Deficiency

Causes: Malabsorption, antibiotics (kill gut bacteria), poor intake

Clinical: Bleeding (variable severity)

Labs:
• PT: Prolonged first (Factor VII has shortest half-life)
• aPTT: Prolonged later (Factors II, IX, X)
• Mixing: Corrects

Treatment: Vitamin K PO (if mild) or IV (if severe/malabsorption)

Liver Disease

Mechanism: Decreased synthesis of all factors (except VIII - made by endothelium)

Clinical: Variable bleeding, often with thrombocytopenia

Labs:
• PT: Prolonged (early sign of liver dysfunction)
• aPTT: Prolonged
• Fibrinogen: Low (late)
• Platelets: Often low (portal HTN → splenomegaly)

Key: Does NOT correct with vitamin K (can't synthesize factors)

Disseminated Intravascular Coagulation (DIC)

Mechanism: Widespread activation of coagulation → consumption of factors & platelets

Causes: Sepsis, trauma, malignancy, obstetric complications

Clinical: Bleeding AND thrombosis simultaneously

Labs:
• PT & aPTT: Both prolonged
• Platelets: Low
• Fibrinogen: Low
• D-dimer: Very high
• Schistocytes on blood smear

Treatment: Treat underlying cause! Supportive (FFP, platelets, cryoprecipitate)

🎯

Bleeding vs. Clotting History Clues

Suggests PLATELET or vWD Problem

Mucocutaneous bleeding (petechiae, purpura)
Epistaxis (frequent, hard to stop)
Gingival bleeding (brushing teeth)
Menorrhagia (heavy periods)
Easy bruising
Prolonged bleeding after minor cuts
Bleeding immediately after trauma/surgery

Suggests COAGULATION FACTOR Problem

Hemarthrosis (bleeding into joints)
Deep muscle hematomas
Retroperitoneal bleeding
CNS hemorrhage
Delayed bleeding (hours after trauma/surgery)
Bleeding that recurs after initial hemostasis
Family history (X-linked in males)

Age of Onset Matters!

Childhood onset + family history: Congenital disorder (hemophilia, vWD, factor deficiency)
Adult onset + no family history: Acquired disorder (liver disease, vitamin K deficiency, medications, acquired hemophilia, DIC)
Neonate with bleeding: Consider hemophilia, vitamin K deficiency (hemorrhagic disease of newborn), Factor XIII deficiency

💊

Interactive Clinical Cases

Test your understanding of coagulation studies with these realistic clinical scenarios!

📋 Case 1: The Boy Who Bruises

History: 4-year-old boy presents with large bruises on his legs after minor playground falls. Mother reports he has always bruised easily. No epistaxis or gingival bleeding. Uncle had similar issues and requires "blood products" before surgeries. No medications.

Labs:
• CBC: Normal (Platelets 250,000)
• PT: 12 seconds (normal)
• aPTT: 65 seconds (elevated; normal 25-35)
• Mixing study: Corrects to 32 seconds

What is the most likely diagnosis?

A. Von Willebrand disease

B. Hemophilia A (Factor VIII deficiency)

C. Lupus anticoagulant

D. Immune thrombocytopenic purpura (ITP)

📋 Case 2: The Warfarin Dilemma

History: 68-year-old woman on warfarin for atrial fibrillation. Stable INR 2.5 for past year. Started antibiotics 5 days ago for UTI. Now presents with dark stools and weakness. No history of GI bleeding.

Examination: Pale, HR 110, BP 100/60. Stool guaiac positive.

Labs:
• Hgb: 8.5 g/dL (was 13.2 last month)
• INR: 6.8
• No active bleeding currently

What is the most appropriate management?

A. Hold warfarin and observe only

B. Hold warfarin + Give vitamin K 2.5-5 mg PO + Monitor closely

C. Give 4-Factor PCC + Vitamin K 10 mg IV immediately

D. Give FFP 4 units + Continue warfarin at lower dose

📋 Case 3: The Mixing Puzzle

History: 32-year-old woman with SLE presents for routine labs. No bleeding symptoms. Had DVT 2 years ago. Two prior miscarriages in first trimester.

Labs:
• CBC: Normal including platelets
• PT: 14 seconds (mildly elevated; normal 11-13)
• aPTT: 58 seconds (elevated; normal 25-35)
• Mixing study: Does NOT correct (remains at 55 seconds)
• Incubation: Still does not correct

What is the most likely diagnosis?

A. Hemophilia A (unlikely - she's female, no bleeding)

C. Acquired Factor VIII inhibitor

C. Antiphospholipid syndrome (lupus anticoagulant)

D. Heparin contamination

📋 Case 4: Post-Operative Bleeding

History: 55-year-old man underwent elective cholecystectomy 3 days ago. Now with bleeding from surgical drain, hematuria, and oozing from IV sites. Recent diagnosis of pancreatic cancer.

Labs:
• Platelets: 45,000 (was 180,000 pre-op)
• PT: 18 seconds (elevated)
• aPTT: 55 seconds (elevated)
• Fibrinogen: 90 mg/dL (normal 200-400)
• D-dimer: >20,000 ng/mL (markedly elevated)
• Blood smear: Schistocytes present

What is the diagnosis and priority treatment?

A. Liver failure; give vitamin K + FFP

B. HIT (heparin-induced thrombocytopenia); stop heparin

C. DIC; treat underlying malignancy + supportive care (transfusions)

D. Vitamin K deficiency; give vitamin K 10 mg IV

Key Takeaways from Cases

Family history + X-linked pattern: Think hemophilia in males; mixing corrects with factor deficiency
Drug interactions with warfarin: Antibiotics (especially metronidazole, TMP-SMX) markedly increase INR; always check INR 3-7 days after starting
SLE + thrombosis + miscarriages + prolonged aPTT that doesn't correct: Classic for antiphospholipid syndrome (thrombosis risk, NOT bleeding!)
Cancer + low platelets + elevated PT/aPTT + low fibrinogen + elevated D-dimer: DIC until proven otherwise; treat underlying cause

📚 Evidence-Based References & Clinical Guidelines

American College of Chest Physicians (ACCP). Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2012.
American Society of Hematology (ASH). Guidelines for Management of Venous Thromboembolism. Blood Advances. 2020.
Clinical and Laboratory Standards Institute (CLSI). H47-A2: One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (aPTT) Test. 2008.
CLSI. H21-A5: Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays. 2008.
Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost. 2001;85(6):958-965.
Keeling D, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-324.
World Health Organization (WHO). Guidelines for the Management of Haemophilia. 2012.
Pengo V, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009;7(10):1737-1740.
Levi M, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33.
Holbrook A, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e152S-e184S.
Douketis JD, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e326S-e350S.
Tomaselli GF, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2017;70(24):3042-3067.

This educational tool follows current evidence-based guidelines from ACCP, ASH, CLSI, and WHO. All content is designed for medical education and should be applied in conjunction with clinical judgment and institutional protocols.